Esperion shares jump 8% on revenue beat, acquisition plans

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices retreat as Trump hints at Iran war end, supply relief Oil demand destruction would likely require prices around $155/bbl: Bernstein Futures rise as Trump says Iran war will end "very soon" - what’s moving markets Gold prices rise but still rangebound with focus on Iran war de-escalation (South Africa Philippines Nigeria) Esperion shares jump 8% on revenue beat, acquisition plans By Editor Rachael Rajan Earnings Editor Rachael Rajan Published 03/10/2026, 07:38 AM Esperion shares jump 8% on revenue beat, acquisition plans 0 ESPR 11.76% ANN ARBOR, Mich. - On Tuesday, Esperion Therapeutics Inc. (NASDAQ:ESPR) reported fourth quarter adjusted earnings per share of $0.22, missing analyst estimates of $0.29, while revenue of $168.4 million slightly exceeded the consensus estimate of $168.28 million. The company’s stock surged 8.22% in pre-market trading following the announcement, driven by strong revenue growth and the company’s agreement to acquire Corstasis Therapeutics. Total revenue for the fourth quarter grew 144% YoY from $69.1 million in the prior year period, while full year 2025 revenue increased 21% YoY to $403.1 million from $332.3 million. U.S. net product revenue rose approximately 38% YoY to $43.7 million in the quarter, matching the full year growth rate of 38% to $159.6 million. The quarter’s collaboration revenue of $124.7 million included a one-time $90 million payment from Otsuka related to regulatory approval and favorable pricing in Japan. "2025 was a defining year for Esperion . We delivered strong growth in our U.S. cardiovascular franchise, broadened access and adoption among statin intolerant or statin-resistant patients and strengthened the durability of our business," said Sheldon Koenig, Chief Executive Officer of Esperion. Fourth quarter retail prescription equivalents grew 34% YoY and 11.3% sequentially. The company reported net income of $61.8 million for the quarter, compar...